{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:13:45Z","timestamp":1754162025907,"version":"3.41.2"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Both ticagrelor and prasugrel are class I recommendations for treatment of ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) [1]. But clinical outcomes with the two drugs are conflicting which might be due to differential effects on coronary microcirculation. No study to date had compared the effects of prasugrel or ticagrelor on coronary microcirculation in patients undergoing pharmacoinvasive PCI (pPCI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim and objective<\/jats:title>\n            <jats:p>To compare the effects of prasugrel and ticagrelor on coronary microcirculation in STEMI patients undergoing pPCI as assessed by Myocardial Blush Grade (MBG). The secondary aim was to assess flow in the infarct-related artery by corrected thrombolysis in myocardial infarction (TIMI) frame count (cTFC) and whether a differential effect if detected on coronary microcirculation translated in improvement in left ventricular ejection fraction assessed at 6\u2005months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material and methods<\/jats:title>\n            <jats:p>A total of 240 patients with STEMI were evaluated in this open-label randomized control trial who initially underwent thrombolysis and later PCI (from 24 to 48\u2005h) post-successful thrombolysis. The study subjects were randomized to receive either ticagrelor (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u2005120) or prasugrel (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u2005120) in 1\u2005:\u20051 ratio 2\u2005h prior to elective PCI. Patients underwent PCI according to standard protocol and post-procedure cTFC and MBG were compared. Patients were also followed up for 6\u2005months to compare ejection fractions in both groups. We also assessed the effect of the two drugs on bleeding complications during hospitalization and over 6-month follow-up period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There were no significant differences between the two groups with respect to baseline characteristics. Prasugrel administration resulted in higher MBG Grade 3 (50.86% vs 33.89%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.012) and lower cTFC (17.14\u2005\u00b1\u20054.08 vs 19.3\u2005\u00b1\u20054.06, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.01). Improvement in ejection fraction was significantly higher with prasugrel compared to ticagrelor (10.29% \u00b1 15.2 vs 4.66% \u00b1 13.5, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.003). Bleeding events at 6\u2005months follow-up according to TIMI classification were similar in both the groups (11.86% vs 6.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.39).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Prasugrel produces greater improvement in coronary microcirculation than Ticagrelor resulting in improved myocardial salvage in patients of STEMI undergoing pPCI.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001265","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T14:01:02Z","timestamp":1689861662000},"page":"381-388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effect of prasugrel versus ticagrelor on coronary microcirculation in patients undergoing pharmacoinvasive strategy \u2013 acute and short-term results"],"prefix":"10.1097","volume":"34","author":[{"given":"Rupesh Santosh","family":"Agrawal","sequence":"first","affiliation":[{"name":"Department of Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Department of Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhawna","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vimal","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saibal","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"Department of Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/eurheartj\/ehq398","article-title":"Routine early coronary angioplasty versus ischaemia-guided angioplasty after thrombolysis in acute ST-elevation myocardial infarction: a meta-analysis.","volume":"32","author":"D\u2019Souza","year":"2011","journal-title":"Eur Heart J"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","article-title":"Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.","volume":"368","author":"Armstrong","year":"2013","journal-title":"N Engl J Med"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"e008059","DOI":"10.1161\/CIRCINTERVENTIONS.119.008059","article-title":"Pharmacoinvasive strategy versus primary percutaneous coronary intervention in ST-elevation myocardial infarction in clinical practice: insights from the vital heart response registry.","volume":"12","author":"Bainey","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"e000133","DOI":"10.1136\/openhrt-2014-000133","article-title":"A prospective, observational, multicentre study comparing tenecteplase facilitated PCI versus primary PCI in Indian patients with STEMI (STEPP-AMI).","volume":"1","author":"Victor","year":"2014","journal-title":"Open Heart"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijcard.2016.12.173","article-title":"P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: analysis from the SAMPA randomized trial.","volume":"230","author":"Guimar\u00e3es","year":"2017","journal-title":"Int J Cardiol"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies.","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"e003508","DOI":"10.1161\/CIRCINTERVENTIONS.115.003508","article-title":"Pharmacoinvasive strategy versus primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction: a propensity score-matched analysis.","volume":"9","author":"Sim","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines.","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.amjcard.2014.06.011","article-title":"Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic reperfusion early after myocardial infarction [STREAM] study).","volume":"114","author":"Welsh","year":"2014","journal-title":"Am J Cardiol"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes.","volume":"381","author":"Schupke","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00134-020-05993-9","article-title":"How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People\u2019s Hospital.","volume":"46","author":"Zeng","year":"2020","journal-title":"Intensive Care Med"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/0002-9149(86)90730-7","article-title":"Noninvasive detection of coronary artery patency using continuous ST-segment monitoring.","volume":"57","author":"Krucoff","year":"1986","journal-title":"Am J Cardiol"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.101.2.125","article-title":"Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.","volume":"101","author":"Gibson","year":"2000","journal-title":"Circulation"},{"issue":"Suppl 3","key":"R19-20250729","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1016\/j.ihj.2018.10.412","article-title":"Correlation of QRS duration with myocardial blush grade as a marker of myocardial reperfusion in primary percutaneous coronary Intervention.","volume":"70","author":"Yusuf","year":"2018","journal-title":"Indian Heart J"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.93.5.879","article-title":"TIMI frame count: a quantitative method of assessing coronary artery flow.","volume":"93","author":"Gibson","year":"1996","journal-title":"Circulation"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.103.21.2550","article-title":"Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.","volume":"103","author":"Gibson","year":"2001","journal-title":"Circulation"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"R23-20250729","first-page":"1187","article-title":"Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: results of an angiographic randomized pilot study.","volume":"87","author":"Mont\u2019Alverne-Filho","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/jth.12907","article-title":"High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis.","volume":"13","author":"Lemesle","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacc.2012.11.032","article-title":"Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.","volume":"61","author":"Wittfeldt","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/CIRCULATIONAHA.118.035931","article-title":"Evaluation of microvascular injury in the revascularized patients with ST-segment-elevation myocardial infarction treated with Ticagrelor versus Prasugrel.","volume":"139","author":"Van Leeuwen","year":"2019","journal-title":"Circulation"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1093\/eurheartj\/ehz917","article-title":"Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study.","volume":"41","author":"Schnorbus","year":"2020","journal-title":"Eur Heart J"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"e001937","DOI":"10.1136\/openhrt-2021-001937","article-title":"Comparative efficacy and safety of oral P2Y12 inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis.","volume":"9","author":"Farmakis","year":"2022","journal-title":"Open Heart"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:02:42Z","timestamp":1753812162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001265","relation":{},"ISSN":["0954-6928"],"issn-type":[{"type":"print","value":"0954-6928"}],"subject":[],"published":{"date-parts":[[2023,7,4]]}}}